Transforming breast cancer detection, ScreenPoint Medical’s Transpara Breast AI integrates seamlessly into Johns Hopkins Medicine’s renowned breast imaging services. This collaboration harnesses cutting-edge technology and clinical expertise to enhance screening accuracy and patient outcomes. Through rigorous evaluation and collaborative implementation, Transpara empowers radiologists to detect cancer earlier and with greater confidence. With FDA clearance and global recognition, Transpara is proven to augment radiologist performance, reduce workload, and streamline workflow. The deployment across seven Johns Hopkins locations signifies a milestone in the fight against breast cancer, promising improved care for patients across the northeast and beyond.
ScreenPoint Medical, a pioneer in medical imaging technology, has announced a significant advancement in the fight against breast cancer: the deployment of its cutting-edge Transpara Breast AI at Johns Hopkins Medicine. This breakthrough technology is set to revolutionize cancer detection for breast cancer screening patients at one of the nation’s foremost medical institutions.
Johns Hopkins Medicine, renowned for its excellence in healthcare and research, including its distinguished Kimmel Cancer Center, stands as a beacon of hope in the battle against cancer. Recognized as a “Center of Excellence” by the National Cancer Institute, Johns Hopkins Medicine conducts an extensive volume of breast imaging exams and interventional procedures annually, underscoring the critical need for advanced diagnostic tools.
The decision to integrate Transpara into the breast imaging services at Johns Hopkins was preceded by meticulous evaluation and scrutiny. The software’s evidence-based approach, effectiveness, and performance were thoroughly assessed, culminating in its selection as the preferred solution by the esteemed breast imaging team at Johns Hopkins.
The implementation process was a collaborative effort between ScreenPoint Medical’s customer success team and the clinical and IT teams at Johns Hopkins. This partnership facilitated the seamless integration of Transpara Breast AI across seven locations within the Johns Hopkins network. The primary objectives of this deployment are to enhance screening workflow, boost decision confidence, and improve breast cancer diagnostic assessment, ultimately leading to earlier detection and reduced recall rates.
Nicki Bryan, VP of Sales at ScreenPoint Medical, expressed elation at Johns Hopkins’ decision to trust their technology in the fight against cancer. She emphasized Transpara’s status as the most clinically validated breast AI available, with a proven track record of empowering radiologists to detect breast cancer at its earliest stages. Bryan also extended gratitude to the professionals at Johns Hopkins for their collaboration, which ensured a smooth transition and integration process.
Transpara’s credentials speak volumes about its reliability and efficacy. With FDA clearance and European MDR approval for use with 2D and 3D mammography systems from multiple manufacturers, Transpara is a globally recognized leader in breast imaging technology. Its adoption by hundreds of leading medical centers in over 30 countries underscores its reputation as a trusted ally in the fight against breast cancer.
One of the most compelling aspects of Transpara is its ability to work in tandem with radiologists, augmenting their expertise and efficiency. Research indicates that Transpara can facilitate the early detection of up to 45% of interval cancers, thereby potentially saving countless lives. Moreover, by streamlining workflow and reducing radiologists’ workload, Transpara enables healthcare providers to optimize resources and prioritize patient care.
The integration of Transpara Breast AI at Johns Hopkins Medicine marks a significant leap forward in the battle against breast cancer. By leveraging cutting-edge technology and clinical expertise, this collaboration promises to revolutionize breast cancer detection, empowering radiologists and benefiting patients across the Northeast. With Transpara’s proven ability to enhance early cancer detection and streamline workflow, the deployment across seven Johns Hopkins locations signals a transformative shift in breast imaging practices. As a trusted ally in the fight against cancer, Transpara embodies the relentless pursuit of excellence and innovation, offering hope to countless individuals affected by breast cancer worldwide.
